Q. Zou

发表

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

A. Zhou, T. Sun, X.Q. Yan, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial

Li Ling, Panpan Liu, Jun Cai, 2024, The Lancet Haematology.